MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (Nasdaq:DEPO) today announced the presentation of data from its Phase 2 study of DM-5689 (formerly referred to as Gabapentin GR®) for the treatment of women with moderate-to-severe menopausal hot flashes. As previously disclosed, DM-5689 significantly reduced the frequency and severity of hot flashes from baseline to the end of treatment compared to placebo in the 124 patient study.
